BioSeeker Group AB Research Reports

Title	Published	Price
Cancer Antibodies: Competitive Positioning for Success By: BioSeeker Group AB Executive Summary This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the \| more...	6/3/2008	$3,100.00
Cancer Vaccines: Aim and Shoot By: BioSeeker Group AB Executive Summary This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline \| more...	5/19/2008	$3,100.00
Cancer Vaccines: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market \| more...	4/20/2008	$2,350.00
Lymphoma Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 180 therapeutics targeting lymphoma, from early preclinical to marketed drugs. Lymphoma Drug Pipeline \| more...	4/20/2008	$2,350.00
Immunotherapy in Oncology: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators \| more...	4/20/2008	$3,100.00
Angiogenesis in Oncology: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary There are today more than 200 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in oncology, from early preclinical to marketed drugs. Angiogenesis in Oncology: Drug Pipeline Update lists all drugs and gives you a \| more...	4/20/2008	$2,350.00
Leukemia Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today more than 240 therapeutics targeting leukemia, from early preclinical to marketed drugs. Leukemia Drug \| more...	4/20/2008	$2,350.00
Prostate Cancer: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the \| more...	4/20/2008	$2,350.00
Apoptosis in Oncology: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. There are \| more...	4/20/2008	$2,350.00
Breast Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall \| more...	4/20/2008	$2,350.00
Antibodies in Oncology: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the \| more...	4/20/2008	$2,350.00
Brain Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the \| more...	4/20/2008	$2,350.00
Hematological Cancers Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There are today more than 390 therapeutics targeting hematological cancers, from early \| more...	4/20/2008	$3,100.00
Liver Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary There are today more than 90 therapeutics targeting liver cancer, from early preclinical to marketed drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each \| more...	4/20/2008	$1,550.00
Pancreatic Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary There are today more than 175 therapeutics targeting pancreatic cancer, from early preclinical to marketed drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each \| more...	4/20/2008	$2,350.00
Ovarian Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication \| more...	4/20/2008	$2,350.00
Renal Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being \| more...	4/20/2008	$2,350.00
Bladder Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 \| more...	4/20/2008	$1,550.00
Melanoma Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival \| more...	4/20/2008	$2,350.00
Colorectal Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a \| more...	4/20/2008	$2,350.00
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top \| more...	4/20/2008	$2,350.00
Lung Cancer Drug Pipeline Update 2008 By: BioSeeker Group AB Executive Summary Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of \| more...	4/20/2008	$2,350.00
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics By: BioSeeker Group AB The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major \| more...	4/1/2008	$3,575.00
Nordic Life Science Industry Guide 2008 By: BioSeeker Group AB The "Nordic Life Science Industry Guide 2008" is a unique CD-ROM product that contains a searchable directory of 1,500 life science companies in Scandinavia (Denmark, Norway, Finland and Sweden). BioSeeker has divided the industry into \| more...	3/18/2008	$299.00
Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology By: BioSeeker Group AB There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have \| more...	3/17/2008	$3,850.00
Title	Published	Price

< prev 1 2 3 4 5 6 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2008, All Rights Reserved, MarketResearch.com
7/24/2008 - 2